Shanton Pharma Meets Primary Endpoint for Phase 2 Study of SAP-001
Feb 09, 2021 / shanton

The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid /eliminate the risk of acute gout attack/reduce and/or eliminate tophi. SAP-001 was well tolerated.